Advertisement

Drug Binding and Drug Effect

  • Ronald J. Tallarida
  • Leonard S. Jacob

Abstract

Drugs that bind readily to a tissue may differ markedly in their ability to produce an effect. In other words, they differ in efficacy or in intrinsic activity. We do not know the reason for these differences; in fact, we do not know very much about the sequence of events between binding and effect. A reasonable explanation would seem to be access to the receptor. Clearly, if the drug molecule cannot arrive at the receptor, then no effect is possible. However, even when access to the receptor is not limited, the effect may not temporally follow the binding. For example, if acetylcholine is administered to a tissue, the effect can rise to a peak and then fall to some lower level, even though the concentration at the receptor is still apparently rising. As a specific example, we mention the work of Lullman and Ziegler,33 who studied the time course of uptake of carbachol by the guinea pig atria and the time course of the effect, decreased contractile force. The time courses of effect and concentration were very different. The effect reached its final value in 2–3 min, whereas the uptake was still in progress even after 30 min. These are just two examples, but there are numerous others which suggest a temporal dependence in the concentration-effect relationship. Thus, access to the receptors is not a general explanation for differences in the efficacy. Furthermore, binding to the tissue may bear no relation to a drug’s ability to produce an effect.

Keywords

Dissociation Constant Drug Binding Pharmacological Method Renal Tubular Secretion Quinuclidinyl Benzilate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Akera, T.: Science, 195: 569, 1977.CrossRefGoogle Scholar
  2. 2.
    Archer, J. A., Gorden, P., and Roth, J.: J. Clin. Invest., 55: 166, 1975.PubMedCrossRefGoogle Scholar
  3. 3.
    Bar, R. S., and Roth, J.: Arch. Intern. Med., 137: 474, 1977.PubMedCrossRefGoogle Scholar
  4. 4.
    Bar, R. S., Gorden, P., and Roth, J: J. Clin. Invest., 58: 1123, 1976.PubMedCrossRefGoogle Scholar
  5. 5.
    Barsoum, G. S., and Gaddum, J. H.: J. Physiol. (London), 85: 1, 1935.Google Scholar
  6. 6.
    Blasig, J., Hollt, V., Herz, A., and Paschelke, G.: Psychopharmacologia, 46: 41, 1976.PubMedCrossRefGoogle Scholar
  7. 7.
    Cantoni, G. L., and Eastman, G.: J. Pharmacol. Exp. Therap., 87: 392, 1946.Google Scholar
  8. 8.
    Cochin, J.: Fed. Proc., 29: 19, 1970.PubMedGoogle Scholar
  9. 9.
    Cochin, J. In Drug Addiction, Experimental Pharmacology. ( Singh, J. M., Miller, L. and Lai, H. eds.) New York, Futura Publishing Co., 1972, p. 365.Google Scholar
  10. 10.
    Cowan, A., Tallarida, R. J., Maslow, J., and Adler, M. W.: Proc. 7th Int. Cong. Pharmacology, Paris, 1978, Abstracts, p. 168.Google Scholar
  11. 11.
    Cox, B. M.: Br. J. Pharmacol., 62: 387P, 1978.PubMedGoogle Scholar
  12. 12.
    Cull-Candy, S. G., Miledi, R., and Trautmann, A.: Nature, 271: 74, 1978.PubMedCrossRefGoogle Scholar
  13. 13.
    Del Castillo, J., and Katz, B.: Proc. R. Soc. London, Ser., B 146: 369. 1957.CrossRefGoogle Scholar
  14. 14.
    Dum, J., Meyer, G., Hollt, V., Herz. A., and Catlin, D. H.: Eur. J. Pharmacol., 46: 165, 1977.PubMedCrossRefGoogle Scholar
  15. 15.
    Furchgott, R. F.: Fed. Proc., 37: 115, 1978.PubMedGoogle Scholar
  16. 16.
    Gero, A.: Arch. Int. Pharmacodyn., 206: 41, 1973.PubMedGoogle Scholar
  17. 17.
    Gero, A.: J. Mol. Medicine, 7: 161, 1976.Google Scholar
  18. 18.
    Giachetti, A., and Shore, P. A.: Life Sci., 21: 89, 1978.CrossRefGoogle Scholar
  19. 19.
    Goldstein, A., Lowney, K. I., and Pal, B. K.: Proc. Natl. Acad. Sci. U.S.A., 68: 1742, 1971.PubMedCrossRefGoogle Scholar
  20. 20.
    Guldberg, C. M., and Waage, P.: In Physical Chemistry (W. J. Moore, ed.), 4th ed. Englewood Cliffs, N.J., Prentice-Hall, 1972, p. 282.Google Scholar
  21. 21.
    Hayashi, G., and Takemori, A. E.: Eur. J. Pharmacol., 76: 63. 1971.CrossRefGoogle Scholar
  22. 22.
    Hogben, C. A., Tocco, D. J., Brodie, B. B., and Schanker, L. S.: J. Pharmacol. Exp. Therap., 725: 275, 1959.Google Scholar
  23. 23.
    Höllt, V., and Herz, A.: Fed. Proc., 37: 158, 1978.PubMedGoogle Scholar
  24. 24.
    Höllt, V., Dum, J., Bläsig, J., Schubert, P., and Herz, A.: Life Sei., 16: 1823, 1975.CrossRefGoogle Scholar
  25. 25.
    Hulme, E. C., Birdsall, N. J. M., Burgen, A. S. V., and Mehta, P.: Mol. Pharmacol., 14: 731, 1978.Google Scholar
  26. 26.
    Janis, R. A., and Triggle, D. J.: J. Pharmacol. Exp. Therap., 24: 602, 1972.Google Scholar
  27. 27.
    Katz, B., and Thesleff, S.: J. Physiol. (London), 138: 63, 1957.Google Scholar
  28. 28.
    Kebabian, J. W., and Calne, D. B.: Nature 277: 93, 1979.PubMedCrossRefGoogle Scholar
  29. 29.
    Koshland, D. E.: Fed. Proc., 23: 719, 1964.PubMedGoogle Scholar
  30. 30.
    La Du, B. N., Mandel, H. G., and Way, E. L.: Fundamentals of Drug Metabolism and Disposition. Baltimore, Williams and Wilkins, 1971.Google Scholar
  31. 31.
    Lee, T., Seeman, P., Rajput, A., Farley, I. J., and Hornykiewicz, O.: Nature, 275: 59, 1978.CrossRefGoogle Scholar
  32. 32.
    Loh, H. L., Law, P. Y., Ostwald, T., Cho, T. M., and Way, E. L.: Fed. Proc., 37: 147, 1978.PubMedGoogle Scholar
  33. 33.
    Lullman, H., and Ziegler, A.: Naunyn-Schmiedebergs Arch. Pharmacol., 280: 1, 1973.CrossRefGoogle Scholar
  34. 34.
    Martin, W. R., Eades, C. G., Thompson, J. A., Huppier, R. E., and Gilbert, P. E.: J. Pharmacol. Exp. Therap., 797: 517, 1976.Google Scholar
  35. 35.
    McGilliard, K. L., Tulunay, F. C., and Takemori, A. E.: In Opiates and Endogenous Opioid Peptides (H. W. Kosterlitz, ed.) Amsterdam, North Holland Publishing Co., 1976, p. 281.Google Scholar
  36. 36.
    McGilliard, K., and Takemori, A. E.: J. Pharmacol. Exp. Ther., 207: 884, 1978.PubMedGoogle Scholar
  37. 37.
    MacNab, M. W. Ph.D. Thesis, Temple University Medical School, Philadelphia, Pa., 1974.Google Scholar
  38. 38.
    Möhler, H., and Okada, T.: Science, 795: 849, 1977.CrossRefGoogle Scholar
  39. 39.
    Mollering, R. C., and Swartz, M. N.: Drug Therapy, 4: 85, 1976.Google Scholar
  40. 40.
    Neu, H. C.: Southern Med. J., 70 (Supp. 1 ): 14, 1977.PubMedGoogle Scholar
  41. 41.
    Olefsky, J. M.: Diabetes, 25: 1154, 1976.PubMedGoogle Scholar
  42. 42.
    Olefsky, J. M., and Reaven, G. M.: J. Clin. Invest., 54: 1323, 1975.CrossRefGoogle Scholar
  43. 43.
    Pert, C. B., and Snyder, S. H.: Science, 779: 1011, 1973.CrossRefGoogle Scholar
  44. 44.
    Rane, A., Wilkinson, G. R., and Shand, D. G.: J. Pharmacol. Exp. Therap., 200: 420, 1977.Google Scholar
  45. 45.
    Rang, H. P., and Ritter, J. M.: Mol. Pharmacol., 6: 357, 1970.PubMedGoogle Scholar
  46. 46.
    Riggs, D. S.: The Mathematical Approach to Physiological Problems. Baltimore, Williams and Wilkins, 1963.Google Scholar
  47. 47.
    Robinson, G. N., and Sutherland, R.: Br. J. Pharmacol., 25: 638, 1965.Google Scholar
  48. 48.
    Schanker, L. S.: Ann. Rev. Pharmacol., 7: 29, 1961.CrossRefGoogle Scholar
  49. 49.
    Shen, J. W., and Way, E. L.: Life Sci., 16: 71, 1975.CrossRefGoogle Scholar
  50. 50.
    Simon, E. J., and Hiller, J. M.: Ann. Rev. Pharmacol. Toxicol., 75: 371, 1978.CrossRefGoogle Scholar
  51. 51.
    Simon, E. J., and Hiller, J. M.: Fed. Proc., 37: 141, 1978.PubMedGoogle Scholar
  52. 52.
    Smits, S. E., and Takemori, A. E.: Br. J. Pharmacol., 39: 627, 1970.PubMedGoogle Scholar
  53. 53.
    Stahl, K. D., Van Bever, W., Janssen, P., and Simon, E. J.: Eur. J. Pharmacol., 46: 199, 1977.PubMedCrossRefGoogle Scholar
  54. 54.
    Szekely, J. I., Dunai-Kovacs, Z., Miglecz, E., Ronai, A. Z., and Bajusz, S.: J. Pharmacol. Exp. Ther., 207: 878, 1978.PubMedGoogle Scholar
  55. 55.
    Takemori, A. E.: In Narcotic Antagonists. M. C. Braude, L. S. Harris, E. L. May, J. P. Smith, and J. E. Villarreal, eds. Advances in Biochemical Psychopharmacology, 8, New York, Raven Press, 1974, p. 335.Google Scholar
  56. 56.
    Tallarida, R. J., Cowan, A., and Adler, M. W.: Life Sciences, 25: 637, 1979.PubMedCrossRefGoogle Scholar
  57. 57.
    Tallarida, R. J., Harakal, C., Rusy, B. F., and Sevy, R. W.: Currents in Modern Biol., 2: 249, 1968.Google Scholar
  58. 58.
    Tallarida, R. J., Harakal, C., Maslow, J., Geller, E. B., and Adler, M. W.: J. Pharmacol. Exp. Ther., 206: 38, 1978.PubMedGoogle Scholar
  59. 59.
    Terenius, L.: Acta Pharmacol. Toxicol., 32: 317, 1973.CrossRefGoogle Scholar
  60. 60.
    Tsai, B. S., and Lefkowitz, R. J.: J. Pharmacol. Exp. Therap., 204: 606, 1978.Google Scholar
  61. 61.
    Tulunay, F. C.: In Characteristics and Function of Opioids (G. M. Van Ree, and L. Terenius, eds.) Amsterdam, Elsevier-North Holland, 1978, p. 495.Google Scholar
  62. 62.
    Wagner, J. G.: Biopharmaceutics and Relevant Pharmacokinetics. Hamilton, III., 1971. Drug Intelligence Publications, 1971.Google Scholar
  63. 63.
    Waud, D. R.: Pharmacol. Rev., 20: 49, 1968.PubMedGoogle Scholar
  64. 64.
    Wilkinson, G. R., and Schenker, S.: Biochem. Pharmacol., 25: 2675, 1976.PubMedCrossRefGoogle Scholar
  65. 65.
    Wohl, A. J., Hausler, L. M., and Roth, F. E.: J. Pharmacol. Exp. Therap., 162: 109, 1968.Google Scholar
  66. 66.
    Yaksh, T. L., and Rudy, T. A.: J. Pharmacol. Exp. Therap., 202: 411, 1977.Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1979

Authors and Affiliations

  • Ronald J. Tallarida
    • 1
  • Leonard S. Jacob
    • 2
    • 3
    • 4
  1. 1.Temple University School of MedicinePhiladelphiaUSA
  2. 2.Department of AnesthesiologyUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  3. 3.Department of PharmacologyUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  4. 4.Medical College of PennsylvaniaPhiladelphiaUSA

Personalised recommendations